Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)

Summary

The National Institutes of Health (NIH) is soliciting applications under a U01 cooperative agreement mechanism for the analytical validation of candidate biomarkers relevant to neurological or neuromuscular disorders. The program aims to support rigorous scientific validation studies that assess the technical performance characteristics of proposed biomarkers. Clinical trials are optionally permitted under this funding opportunity. The opportunity is posted on Grants.gov under PAR-25-050 and spans a multi-year open window from October 2024 through June 2026.

How they evaluate

Risks & flags

• Extremely long open window (nearly 2 years) with rolling submissions — may favor well-resourced academic medical centers already engaged with NIH program officers
• U01 cooperative agreement mechanism implies significant NIH involvement in study design, which may advantage applicants with existing NIH relationships